



Rosetta Biosoftware and GeneGo to Offer Interoperability between the Rosetta Resolver® System and MetaCore™

SEATTLE, Wash., and ST. JOSEPH, Mich., July 18, 2005 - Rosetta Biosoftware and GeneGo, Inc. today announced a collaboration to establish interoperability between Rosetta Biosoftware's Resolver system and GeneGo's MetaCore system. Researchers will be able to easily exchange data between the MetaCore and Resolver systems to leverage both systems' ability to analyze gene expression data and perform sophisticated pathway analysis.

The Rosetta Resolver system is a versatile and robust comprehensive gene expression data analysis system that enables research organizations to efficiently and effectively conduct life-saving discoveries and develop drugs. The MetaCore system is an integrated platform that includes a software suite for functional analysis of microarrays, Serial Analysis of Gene Expression (SAGE), proteomics, metabolomics and other high throughput experimental data. The platform is based on a unique, manually-curated database of human protein-protein and protein-DNA interactions, transcriptional factors, signaling, metabolism, and bioactive molecules.

"Rosetta Biosoftware's collaboration with GeneGo supports our customers' desire to analyze data in the Rosetta Resolver system in conjunction with pathway information from MetaCore," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "Our mutual customers will now be able to combine the Resolver system's powerful analysis tools with the MetaCore system's comprehensive pathways to determine on- and off-target effects and to enrich gene expression data with biological context."

"GeneGo is pleased to be working with Rosetta Biosoftware in response to customers asking for the two companies to smoothly integrate their platforms so they can follow a daily workflow from expression analysis through to pathway analysis and visualization in an iterative easy to use manner," said Julie Bryant, vice president of business development.

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of

experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of comprehensive bioinformatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

MetaCore, MetaBase and MetaDrug are trademarks of GeneGo, Inc.

Editorial Contact:

For Rosetta Biosoftware:
Myra Ozaeta
+1 206 926 1288

For GeneGo:
Julie Bryant
+1 858 756 7996